Case Details for "IDM Pharma, Inc"

Investigation related to proposed acquisition of IDM Pharma

Lawyers are investigating potential shareholder claims arising from the proposed acquisition of IDM Pharma, Inc. ("IDM" or the "Company") (Nasdaq:IDMI) by Takeda Pharmaceutical Co. Under the terms of the merger agreement, IDM shareholders will receive $2.64 per share, valuing the transaction at approximately $66.7 million. The investigation is focused on the potential unfairness of the merger price and of the process by which the IDM Board of Directors approved the agreement.

Posted on:05/20/2009
Company: IDM Pharma, Inc
Affected Class: Current shareholders of IDM Pharma, Inc.
Scope: Nationwide

Contact Us Regarding This Investigation:

First Name
Last Name
Email Address
Phone Number
State of Residence	Please select Outside of US or Canada Canada Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware District Of Columbia Florida Georgia Guam Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Palau Pennsylvania Puerto Rico Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virgin Islands Virginia Washington West Virginia Wisconsin Wyoming
Name of Company At Issue
Description / Explanation
Security Code Please enter the code provided in the text box to submit this form.